Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAggressive LymphomasIndolent LymphomasTransplantationDiseaseChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaStem Cell Transplantation, AllogeneicStem Cell Transplantation, AutologousSubgroupICD10C81.-C82.-C82.7C82.9C83.0C83.1C83.3C88.0-C91.1-Z94.80MeSHHematopoietic Stem Cell TransplantationHodgkin DiseaseLeukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularTransplantation, AutologousTransplantation ConditioningSequenceChemotherapyChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabNo. Substances6 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleCyclophosphamideCytarabineDexamethasoneDimetindenEtoposideFluconazoleFludarabineFosaprepitantFurosemideGranisetronMelphalanMesnaParacetamolPegfilgrastimPrednisoloneRituximabThiotepaUrsodeoxycholic acidValaciclovirSupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleCyclophosphamideCytarabineDexamethasoneDimetindenEtoposideFluconazoleFludarabineFosaprepitantFurosemideGranisetronMelphalanMesnaParacetamolPegfilgrastimPrednisoloneRituximabThiotepaUrsodeoxycholic acidValaciclovirSupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleCyclophosphamideCytarabineDexamethasoneDimetindenEtoposideFluconazoleFludarabineFosaprepitantFurosemideGranisetronMelphalanMesnaParacetamolPegfilgrastimPrednisoloneRituximabThiotepaUrsodeoxycholic acidValaciclovirSupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleCyclophosphamideCytarabineDexamethasoneDimetindenEtoposideFluconazoleFludarabineFosaprepitantFurosemideGranisetronMelphalanMesnaParacetamolPegfilgrastimPrednisoloneRituximabThiotepaUrsodeoxycholic acidValaciclovirNo. Substances61117Protocol classificationTherapy classificationalternativecurrent standardIntensityHochdosis, myeloablativ, bei autologer SZTKonditionierung, nicht-myeloablativ (NMA)Standard doseTherapy indicationRelapse therapyseveral possibleTherapy phaseallogene Stammzelltransplantationautologous stem cell transplantationSalvageTherapy intentioncurativeRisksDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaMucositis only studiesPublicationAuthorDuléry RKhouri IFKirschey SDiseaseCLL, FL Grad I-IIIa, vor allogener SZTNHL oder HL, auto-SZTrezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2OriginCentre de Recherche Saint-Antoine, Sorbonne University, Paris, FranceDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzUniversity of Texas M. D. Anderson Cancer Center, Houston, USAProtokolle in Überarbeitung 3 protocols foundR-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)Rituximab 375 / Fludarabine 30 / Cyclophosphamide 750, follicular lymphoma, stages I–IIIa, Allogeneic Stem Cell Transplantation, NMA (PID3223 V1.0)Revision: TEAM - Thiotepa 8 / Etoposid 100 / Cytarabin 200 / Melphalan 200, autologe Stammzelltransplantation (PID406 V2.1)
